Aripiprazole Tablet
Product Images NDC 68071-3725

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-3725). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3725 3)

Aripiprazole 2 mg tablets label from NuCare Pharmaceuticals, Inc. This prescription drug bottle label features the NDC 68071-3725-3 with a package count of 30 tablets. It includes manufacturer details from Alkem Laboratories Ltd., India, and storage instructions to keep at controlled temperature (68-77°F). The label also displays barcodes, lot number, expiration placeholder, and patient instructions to take the medication daily per doctor directions.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier curve chart depicting the proportion of subjects with relapse over days from randomization. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse ranging from 0 to 1. Two lines compare Aripiprazole and placebo groups, with subject counts at risk displayed below the x-axis.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A survival curve chart comparing proportion with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from 0 to 364, and the y-axis shows proportion with relapse from 0 to 1. The chart includes a decreasing number of subjects at risk over time for both groups, with Aripiprazole consistently showing a lower relapse proportion than placebo.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic graph showing the fold change and 90% confidence interval of dehydro-aripiprazole levels (AUC and Cmax) when co-administered with various CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam. The x-axis represents the change relative to reference without interacting drug.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart depicting fold changes and 90% confidence intervals for pharmacokinetic parameters such as AUC and Cmax of various drugs (including dextrorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram) relative to a reference without interacting drugs. The horizontal axis shows change relative to reference on a scale from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic (PK) chart showing aripiprazole fold change and 90% confidence intervals for various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference, and the y-axis lists the factors compared with their respective AUC and Cmax values.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the impact of factors such as CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment on AUC and Cmax relative to reference values. The horizontal axis represents change relative to reference, ranging from 0.5 to 3.0, with error bars depicting 90% confidence intervals for each comparison.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' illustrating the change in AUC and Cmax relative to reference without interacting drugs. It compares effects of CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam on Aripiprazole levels.*

FDA Label Image

Aripiprazole-fig-18 (Aripiprazole Fig 18)

A line graph showing the change in YGTSS total TIC score from baseline over 8 weeks of treatment. It compares Aripiprazole at low and high doses with a placebo, illustrating changes in least-squares mean scores across treatment weeks.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of aripiprazole, showing the arrangement of its atoms and bonds including two chlorine atoms on a phenyl ring, a piperazine ring, and other key molecular features.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier type plot comparing the proportion of subjects with relapse over days from randomization for two groups: Aripiprazole (blue solid line) and Placebo (red dashed line). The graph includes the number of subjects at risk at various time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.